N4 Pharma PLC Granting of Patents (0490A)
31 Januar 2022 - 7:59AM
UK Regulatory
TIDMN4P
RNS Number : 0490A
N4 Pharma PLC
31 January 2022
31 January 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Granting of Patents
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces that the University of Queensland has
informed the Company that it has been notified by the US patent
attorney of the granting of its patent application in relation to
Nuvec(R) in the United States and by the Chinese authorities of the
granting of a patent in China. N4 Pharma has the exclusive
worldwide rights to Nuvec(R) for therapeutic uses in humans and
animals.
The granted patent in the USA will specifically cover the matter
of composition of the nanoparticle made using a broad description
of the manufacturing process used by the Company. The University of
Queensland has also informed the Company it will file a
continuation patent application in the USA for a matter of
composition patent independent of the manufacturing process to
match the patents granted in Europe, Japan, Australia and
China.
Nigel Theobald, Chief Executive Officer of the Company,
commented : "We are delighted to receive notification of this
allowance to grant our licensed patent in these critical and
influential markets.
"The granting of this USA nanoparticle patent using a broad
description of the manufacturing process adds to the other granted
patents giving us strong intellectual property protection in the
key territories across the world which is a vital component for
potential licensing deals"
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 which has been
incorporated into UK law by the European Union (Withdrawal) Act
2018.
Enquiries:
N4 Pharma Plc Via IFC Advisory
Nigel Theobald, CEO
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: + 44 (0)20 3470 0470
Nominated Adviser and Joint
Broker
Matthew Johnson/Caroline Rowe
(Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
Turner Pope Investments (TPI) Tel: +44 (0)20 3657 0050
Limited
Joint Broker
Andy Thacker
IFC Advisory Limited Tel: +44 (0)20 3934 6630
Financial PR
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBKFBNOBKDPDB
(END) Dow Jones Newswires
January 31, 2022 01:59 ET (06:59 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024